New developments in the treatment of castration resistant prostate cancer

被引：4
|
作者：
Wadia, Roxanne [1 ]
Petrylak, Daniel P. [1 ]
机构：
[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, Smilow Canc Ctr,Dept Med, New Haven, CT 06520 USA
来源：
ASIAN JOURNAL OF ANDROLOGY | 2014年 / 16卷 / 04期
关键词：
castration resistant prostate cancer; abiraterone; enzalutamide; chemotherapy; docetaxel; cabazitaxel; PSMA antibody; ANDROGEN RECEPTOR GENE; TMPRSS2-ERG FUSION TRANSCRIPTS; PHASE-III TRIAL; SIPULEUCEL-T; DOUBLE-BLIND; ABIRATERONE ACETATE; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; DOCETAXEL; PLACEBO;
D O I：
10.4103/1008-682X.127824
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer (CRPC) have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for the development of new drugs to target prostate cancer, and our understanding of genetic mutations may give us new tools with which to more accurately diagnose and be able to predict the course of this heterogeneous disease. This article summarizes the recent advances in the understanding of the development of CRPC, as well as the new drugs and targets, which have evolved from this basic research.
引用
收藏
页码：555 / 560
页数：6
相关论文
共 50 条
  • [1] New Developments in the Treatment of Castration-Resistant Prostate Cancer
    Higano, Celestia S.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (5.5): : 773 - 776
  • [2] New Treatment Options in Castration-Resistant Prostate Cancer
    Armstrong, Andrew J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 690 - 693
  • [3] New treatment options for castration-resistant prostate cancer
    Simondsen, Katherine
    Kolesar, Jill
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 856 - 865
  • [4] Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
    Sridhar, Srikala S.
    Freedland, Stephen J.
    Gleave, Martin E.
    Higano, Celestia
    Mulders, Peter
    Parker, Chris
    Sartor, Oliver
    Saad, Fred
    [J]. EUROPEAN UROLOGY, 2014, 65 (02) : 289 - 299
  • [5] Treatment of Nonmetastatic Castration Resistant Prostate Cancer
    Luo, Jia
    Beer, Tomasz M.
    Graff, Julie N.
    [J]. ONCOLOGY-NEW YORK, 2016, 30 (04): : 336 - 344
  • [6] New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer
    Maffioli, L.
    Florimonte, L.
    Costa, D. C.
    Castanheira, J. Correia
    Grana, C.
    Luster, M.
    Bodei, L.
    Chinol, M.
    [J]. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (04): : 420 - 438
  • [7] New treatment options in castration resistant prostate cancer: denosumab, alpharadin
    Gemalmaz, Hakan
    [J]. UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 118 - 122
  • [8] New and emerging agents for the treatment of castration-resistant prostate cancer
    Higano, Celestia S.
    Crawford, E. David
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) : S1 - S8
  • [9] Cabazitaxel: A New Treatment for Metastatic Castration-Resistant Prostate Cancer
    Schwartz, Joanna R.
    Bottiglieri, Salvatore M.
    [J]. AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2013, 7 (01) : 66 - 72
  • [10] Enzalutamide - a new agent for treatment of castration-resistant prostate cancer
    Wysocki, Piotr J.
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (05): : 186 - 190
12345